nirmatrelvirritonavir sell brand name paxlovid combin two antivir drug nirmatrelvir ritonavir use treatment covid decemb combin grant emerg use author food drug administr fda treatment coronavirus diseas covid copackag medic sell brand name paxlovid paxlovid author preexposur postexposur prevent covid initi treatment requir hospit due sever critic covid decemb uk medicin healthcar product regulatori agenc mhra approv combin peopl mild moder covid high risk develop sever covid paxlovid indic treatment mildtomoder coronavirus diseas covid peopl age twelv year age old weigh least kilogram lb posit result direct sarscov test high risk progress sever covid includ hospit death copackag medic author preexposur postexposur prevent covid initi treatment requir hospit due sever critic covid human datum use nirmatrelvir pregnanc relat risk birth defect miscarriag advers outcom also human datum presenc nirmatrelvir human milk effect milk product infant pregnant rabbit reduct fetal bodi weight observ system exposur time high author human dose paxlovid temporari reduct bodi weight observ offspr nurs rat coadministr certain medic may result serious sometim fatal interact drug contraind hypersensit nirmatrelvir ritonavir sever reduc kidney liver function coadminister certain drug depend cypa clearanc elev concentr result serious reaction potent cypa induc reduc plasma concentr nirmatrelvir ritonavir may result loss virolog respons possibl resist among coadministr also interfer concentr sever drug sometim requir dose adjust care monitor drug also recommend pregnanc breastfeed stop treatment advers event paxlovid regardless causal observ phase iiiii epichr studi includ dysgeusia diarrhea vomit hypertens myalgia specif antidot overdos paxlovid treatment consist support measur monitor vital sign observ clinic status uk place order cours octob australia preorder cours drug secur million cours billion novemb pfizer submit applic food drug administr fda emerg use author combin author grant decemb european medicin agenc ema issu guidanc use paxlovid treatment covid eu decemb isra ministri health approv use paxlovid decemb south korea approv use paxlovid decemb uk medicin healthcar product regulatori agenc mhra grant condit approv paxlovid decemb combin sometim fals claim repackag version antiparasit drug ivermectin promot covid therapeut claim sometim use nicknam pfizermectin reli superfici similar pharmacokinet drug claim pfizer suppress benefit ivermectin effect covid concentr ivermectin blood would requir dose time high safe septemb pfizer begin phase iiiii trial nirmatrelvir combin ritonavir decemb pfizer complet phase iii studi nirmatrelvir combin ritonavir decemb pfizer announc result phase iiiii studi nirmatrelvir combin ritonavir result show reduc risk hospit death decemb unit kingdom medicin healthcar product regulatori agenc mhra approv use nirmatrelvir combin ritonavir adult mild moder infect high risk ill worsen efficaci combin hospit death adult outpati administ within five day symptom onset ci